Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.

Fonterelli SPAC 2 Aktie 118813979 / DE000A3MQR65

01.10.2025 09:33:14

EQS-News: Viromed Medical AG drives forward market launch of new products in the first half of 2025 and expands strategic partnerships

EQS-News: Viromed Medical AG / Key word(s): Half Year Report/Half Year Results
Viromed Medical AG drives forward market launch of new products in the first half of 2025 and expands strategic partnerships

01.10.2025 / 09:33 CET/CEST
The issuer is solely responsible for the content of this announcement.


PRESS RELEASE

Viromed Medical AG drives forward market launch of new products in the first half of 2025 and expands strategic partnerships

Rellingen, October 01, 2025 – Viromed Medical Group ("Viromed"; ISIN: DE000A3MQR65), a medical technology company and pioneer of cold plasma technology, has published its 2025 half-year report, which includes consolidated interim financial statements for the first time. The company can look back on a successful first half of 2025, which was marked by a strategic acquisition, new collaborations, and promising study results. Operational activities focused on the development of further products based on innovative cold plasma technology, preparations for approvals, and the conduct of preclinical and clinical studies.

With the integration of pharmedix GmbH, Viromed expanded its portfolio to include healthcare products in the fields of medicine, nutrition, and cosmetics. The collaboration with relyon plasma GmbH secured the series production of the innovative cold plasma products ViroCAP® and PulmoPlas®. Viromed also made significant progress in clinical development: initial results in the treatment of ventilator-associated pneumonia (VAP) in intensive care patients confirmed the high potential of PulmoPlas®. This was complemented by exclusive distribution partnerships in Asia, in the veterinary sector, and in the European cosmetics market, which are opening up new growth markets. Recent preclinical study data from the Hannover Medical School (MHH) underscore the great medical potential of cold plasma therapy, which could prevent thousands of deaths each year.

With the first-time consolidation of Viromed Medical AG, Viromed Medical GmbH, and pharmedix GmbH, the economic situation is now presented at group level. Consolidated revenues of EUR 2.4 million were achieved in the first half of 2025. Overall, there was a net loss for the period of EUR 0.8 million, mainly due to expenses for the preparation of the market launch of ViroCAP® and PulmoPlas®. The company's equity amounted to EUR 6.6 million as of June 30, 2025, corresponding to an equity ratio of 39.9%.

Viromed plans significant growth for 2025 and confirms its forecast for the full year. The Viromed Medical Group's revenue is expected to rise from EUR 1.37 million in 2024 to between EUR 8 million and EUR 10 million. The company also expects a slightly positive result, primarily driven by the operating business of the acquired pharmedix GmbH.

The 2025 half-year financial statements are available on the Viromed Medical AG website.

 

About Viromed Medical AG

Viromed Medical AG specializes in the development, manufacture and distribution of medical products. The operating business of the company, which has been listed on the stock exchange since October 2022, focuses on the distribution of innovative cold plasma technology for medical applications via its wholly owned subsidiary Viromed Medical GmbH. Viromed can draw on a broad customer base in the DACH region and beyond. Viromed is pursuing the goal of further advancing the use of cold plasma technology in medicine in the coming years and realizing the corresponding growth potential.

www.viromed-medical-ag.de


Contact Viromed

E-Mail: kontakt@viromed-medical.de
 

Press contact

E-mail: viromed@kirchhoff.de



01.10.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Viromed Medical AG
Hauptstrasse 105
25462 Rellingen
Germany
E-mail: kontakt@viromed-medical.de
Internet: https://www.viromed-medical-ag.de/
ISIN: DE000A3MQR65
WKN: A3MQR6
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Hamburg, Tradegate Exchange
EQS News ID: 2206704

 
End of News EQS News Service

2206704  01.10.2025 CET/CEST

Analysen zu Fonterelli SPAC 2 AG Inhaber-Akt

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
  • ?
Zu diesem Datensatz liegen uns leider keine Daten vor.
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

Let’s talk about Börsenjahr 2025 | Börsentag Zürich 2025

Ein besonderes Highlight des Börsentag Zürich 2025 war die grosse Diskussionsrunde mit:
👉 Thomas B. Kovacs (Sparkojote)
👉 Robert Halver (Baader Bank)
👉 Tim Schäfer (Finanzblogger, New York)
👉 Lars Erichsen (Börsencoach & YouTuber)
👉 David Kunz (COO, BX Swiss)

Gemeinsam analysieren sie die Entwicklungen an den Finanzmärkten 2025, teilen Einschätzungen zu aktuellen Trends und geben spannende Einblicke für Anleger.

📌 Themen im Fokus:
🔹Welche Krisen & geopolitischen Risiken beschäftigen die Märkte wirklich?
🔹Wie wirken sich Zölle speziell auf die Schweiz und ihre Exportwirtschaft aus?
🔹Zinspolitik: Unterschiede zwischen USA, Europa und Schweiz.
🔹Aktien vs. Immobilien: Welche Assetklasse lohnt sich 2025 mehr?
🔹Künstliche Intelligenz – Hype oder langfristiger Wachstumstreiber?
🔹Gold vs. Bitcoin: Welches Asset ist der bessere Schutz im Depot?
🔹Inflation, Liquidität und Notenbanken: Warum Sachwerte profitieren.
🔹Blick in die Glaskugel: Wo stehen Aktien & Krypto Ende 2025?

Ein besonderes Highlight auf dem diesjährigen Börsentag Zürich war die BX Swiss Blogger-Lounge. Bekannte YouTuber und Finanz-Influencer standen für Gespräche und Diskussionen bereit und vermittelten Ihr Wissen und Ihre Erfahrungen in Vorträgen.

👉🏽 Jetzt auch auf BXplus anmelden und von exklusiven Inhalten rund um Investment & Trading profitieren!

Krise überall – Börse steigt trotzdem! | Börsentag Zürich 2025

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 12’784.72 19.99 S2S3KU
Short 13’063.09 13.66 UBSIIU
Short 13’539.65 8.91 BWCSGU
SMI-Kurs: 12’346.94 01.10.2025 17:14:06
Long 11’763.82 18.91 SG1BPU
Long 11’507.52 13.58 BO0SVU
Long 11’036.43 8.97 BQFSFU
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com

finanzen.net News

Datum Titel
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
{{ARTIKEL.NEWS.BODY.TITEL}}